蛋白琥珀酸铁口服液治疗异常子宫出血继发性贫血临床研究

Clinical study of protein iron succinate oral liquid in treating anemia secondary to abnormal uterine bleeding

目的 探讨蛋白琥珀酸铁口服液治疗异常子宫出血继发性贫血的有效性及安全性。方法 收集2021年4月至2022年9月在黑龙江中医药大学附属第一医院妇科被确诊为异常子宫出血继发性贫血的150例患者纳入研究,所有患者均在对症止血治疗的基础上,采用蛋白琥珀酸铁口服溶液(盛雪元)治疗,观察治疗后第2周和第4周的临床总有效率,血红蛋白、血清铁、血清铁蛋白等疗效指标变化情况及不良反应发生情况。结果 治疗后2周临床总有效率为75.3%,治疗后4周临床总有效率为90.4%,二者比较差异有统计学意义(χ^(2)=11.680,P<0.05);治疗后,血红蛋白、血清铁、血清铁蛋白水平与治疗前比均上升,差异均有统计学意义(P<0.05);总铁结合力与治疗前比下降,差异有统计学意义(P<0.05),且治疗后4周各项指标的恢复情况较治疗后2周显著。治疗后无不良反应发生。结论 蛋白琥珀酸铁口服液治疗妇科异常子宫出血继发性贫血有很好的疗效并具有安全性,值得临床推广。

Objective To explore the efficacy and safety of iron protein succinate oral liquid in the treatment of anemia secondary to abnormal uterine bleeding in women.Methods Totally 150 patients,who were diagnosed with secondary anemia due to abnormal uterine bleeding in the Department of Gynecology of the First Affiliated Hospital of Heilongjiang University of Chinese Medicine from April 2021 to September 2022,were included in the study.All patients were treated with protein iron succinate oral solution(Sheng Xueyuan)on the basis of symptomatic hemostasis treatment.The clinical total effective rate,changes in efficacy indicators such as hemoglobin,serum iron,serum ferritin,and the incidence of adverse reactions were observed in the second and fourth weeks after treatment.Results The total clinical effective rate was 75.3%after 2 weeks of treatment,and 90.4%after 4 week of treatment(χ^(2)=11.680,P<0.05).After treatment,hemoglobin,serum iron,and serum ferritin increased significantly compared with those before treatment(P<0.05),and total iron binding force decreased significantly compared with those before treatment(P<0.05),and the recovery of various indicators at 4 weeks of treatment was significantly higher than that at 2 weeks of treatment.No adverse reactions occurred after treatment.Conclusion Protein iron succinate oral liquid has good efficacy and safety in the treatment of secondary anemia caused by gynecological abnormal uterine bleeding,and is worthy of clinical promotion.